Transgene Announces Financial Calendar for 2018

STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News:

Transgene (Paris: TNG) today announced its financial reporting dates for 2018:

About TransgeneTransgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical and preclinical development, including TG1050 (chronic hepatitis B) and TG6002 (solid tumors). Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China.Additional information about Transgene is available at www.transgene.fr.Follow us on Twitter: @TransgeneSA

View source version on businesswire.com: http://www.businesswire.com/news/home/20171221005609/en/

Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director Corporate Communications & IR
[email protected]
or
Media:
Citigate Dewe Rogerson
David Dible / Marine Perrier, + 44 (0)20 7638 9571
[email protected]

Source: Transgene

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight
• Cerebras Q1 EPS miss sends shares down 9% after-hours